Apnimed was founded in 2017 by Lawrence G. Miller and Luigi Taranto Montemurro. The company has not publicly endorsed plans to participate in an IPO.
Apnimed is a pharmaceutical company developing oral pharmacologic treatments for obstructive sleep apnea and other related disorders. As of January 2023, the company's AD109 treatment is still in development, but has been granted fast track status by the FDA. Apnimed has raised more than $200 million in venture capital funding from investors including Alpha Wave Ventures, Sectoral Asset Management, Columbia-Seligman Investments, and Tao Capital Partners. A Series C funding round in late 2022 was extended after being oversubscribed, bringing in a total of $142.25 million in fresh capital. The company did not, however, disclose valuation figures.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Apnimed does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Apnimed will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 12/22/2022 | Series C-3 | $366.58MM | $XXX.XX | $XXX.XX |
| 5/4/2022 | Series C-1 and C-2 | $268.69MM | $XXX.XX | $XXX.XX |
| 3/25/2021 | Series B | $156.17MM | $XXX.XX | $XXX.XX |
| 3/31/2020 | Series A-2 | $98.94MM | $XXX.XX | $XXX.XX |
| 6/25/2018 | Series A | $57.26MM | $XXX.XX | $XXX.XX |
Apnimed is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Apnimed pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Apnimed is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
